Triple immunosuppression reduces mononuclear cell infiltration and prolongs graft life in pig–to–newborn baboon cardiac xenotransplantation  by Minanov, Oktavijan P. et al.
TRIPLE IMMUNOSUPPRESSION REDUCES MONONUCLEAR CELL INFILTRATION AND
PROLONGS GRAFT LIFE IN PIG–TO–NEWBORN BABOON CARDIAC XENOTRANSPLANTATION
Oktavijan P. Minanov, MDa,b
John H. Artrip, MDa,b
Matthias Szabolcs, MDc
Pawel A. Kwiatkowski, MDa,b
Uri Galili, PhDd
Silviu Itescu, MDa,b
Robert E. Michler, MDa,b,e
Objective: Pig hearts transplanted into unmedicated newborn baboons do
not undergo hyperacute rejection by preformed xenoantibody and comple-
ment. These grafts are rejected at days 3 to 4 in association with the
infiltration of macrophages and natural killer cells. We investigated
whether an immunosuppressive regimen used widely in cardiac allotrans-
plantation could reduce this cellular response and prolong xenograft life.
Methods: Ten newborn baboons underwent heterotopic pig cardiac xeno-
transplantation. Five baboons were immunosuppressed with mycopheno-
late mofetil (100 mg/kg), methylprednisolone acetate (0.8 mg/kg), and
cyclosporine A (INN: ciclosporin; 10 mg/kg). Xenograft rejection was
studied by light microscopy and immunofluorescence. The induced hu-
moral response to porcine xenoantigens was documented by enzyme-linked
immunosorbent assay using synthetic a-1,3-galactosyl epitopes coupled to
bovine serum albumin. Results: Graft life was extended from a mean of
3.6 6 0.5 days (n 5 5) to a mean of 6.2 6 1.1 days (n 5 5, p 5 0.01). In
comparison with controls, explanted grafts from medicated baboons dem-
onstrated reduced infiltration with natural killer cells and macrophages,
but increased evidence of complement-mediated rejection substantiated by
increased deposition of immunoglobulin M, complement, and fibrin. In all
baboons receiving transplants, levels of both immunoglobulin M and
immunoglobulin G anti-galactose were significantly increased after trans-
plantation, with immunoglobulin G levels remaining persistently elevated.
Conclusions: These results indicate that cyclosporine-based triple immuno-
suppression marginally prolonged xenograft survival and appears to have
reduced the natural killer cell and macrophage infiltrates. The immuno-
suppressive protocol, however, was not adequate to prevent the induced
immunoglobulin M humoral response and prevent complement-mediated
graft injury. (J Thorac Cardiovasc Surg 1998;115:998-1006)
Cardiac transplantation has progressed to thepoint at which it currently represents the best
therapeutic option available to patients with end-
stage heart disease. The supply of human donor
hearts, however, remains inadequate to meet the
ever-increasing demand. The severe shortage of
donor hearts is especially acute in the pediatric
population. This situation has been further exacer-
bated by the inability to use mechanical assist de-
vices as “a bridge,” sustaining pediatric patients in
need of a heart transplant until an appropriate
donor is located. This situation has prompted the
investigation of xenografts as an alternative source
of organs for human beings. The similar physiology
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and size of pig and human organs, the ease with
which pigs can be bred in large numbers, and their
relative lack of pathogens capable of causing infec-
tion in human beings make pigs an attractive source
of organs.
Mature primates contain high levels of preformed
immunoglobulin M (IgM) xenoantibody, and grafts
transplanted into these animals undergo hyperacute
rejection within minutes to hours.1 These preformed
xenoantibodies are primarily directed to the
epitope, Gal-a-1-3-Gal b-1-4-GlcNAc-R (a-Gal).2
Expression of the a-Gal residue on cells depends on
the presence of a functional gene encoding for the
a-1,3-galactosyltransferase glycosidation enzyme.
The phylogenetically related group of primates,
which includes human beings, apes, and Old World
monkeys (the platyrrhines), contains an inactivated
a-1,3-galactosyltransferase gene and does not ex-
press a-Gal on cell surface structures. In contrast,
all other mammalian species contain an intact a-1,3-
galactosyltransferase gene and express a-Gal on
endothelium and other cell lines.3
It is thought that anti-Gal antibodies initially
develop in human beings, apes, and Old World
monkeys after exposure to gut bacterial flora, which
also express the a-Gal epitope.4 Because the new-
born gut is sterile, there is an immunologic window
during which newborn primates do not have IgM
anti-Gal antibodies and do have reduced levels of
IgG anti-Gal antibodies. Indeed, IgM xenoantibod-
ies are nearly absent in the serum of newborn
human beings and primates and progressively in-
crease to reach adult levels by 2 months of age. As
for xenoreactive IgG antibody levels, those in new-
born infants are approximately 25% of those in
adults, reflecting passive transfer of maternal IgG
across the placenta.5, 6 Because newborn human
beings and baboons have very low levels of anti-Gal
IgM antibodies and reduced levels of anti-Gal IgG
antibodies, newborns serve as a natural model of
antibody depletion and pig hearts transplanted into
baboons do not undergo hyperacute rejection.7
Rather, we have previously shown that these grafts
are rejected at days 3 to 4. This rejection process is
associated with an infiltration of mononuclear cells
(predominately natural killer cells and macro-
phages) and an induced humoral response.8, 9 The
Fig. 1. Micrograph at low power of a heterotopic pig cardiac xenograft placed into an unmedicated
newborn baboon. This specimen demonstrates a dense mononuclear cell infiltrate. Tissue was obtained at
the time of rejection (4 days). This specimen is representative of all control grafts.
Table I. Graft survival
Control Medicated
Baboon Graft life (days) Baboon Graft life (days)
1 4 1 6
2 3 2 6
3 3 3 6
4 4 4 5
5 4 5 8
Average age
36 days
(28–43)
Mean 3.6 6 0.5 Average age
38 days
(34–40)
Mean 6.2 6 1.1
p 5 0.01
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importance of natural killer cells and macrophages
was first observed in complement-depleted rat re-
cipients of heterotopic guinea pig cardiac xeno-
grafts.10 This phenomena has been termed “delayed
xenograft rejection” and is distinct in its time course
and pathogenesis from T cell–mediated rejection
seen in acute allograft rejection.
It has yet to be determined whether “delayed
xenograft rejection” in primates can be abated with
conventional immunosuppression. Therefore this
study sought to investigate the effects of a cyclospo-
rine-based immunosuppressive protocol (INN:
ciclosporin), analogous to those used in allotrans-
plantation, on “delayed xenograft rejection” in new-
born baboon recipients of pig cardiac xenografts.
Materials and methods
Animals. Newborn baboons (Papio anubis) were born
at the Institute for Comparative Medicine (Columbia
University, New York, N.Y.). Expectant mothers were
purchased from Biologic Resources Laboratory, Chicago,
Illinois. Day-old Yorkshire pigs weighing 1000 gm were
purchased from Animal Biotech Industries, Inc., Dan-
boro, Pennsylvania, and used as donors. Approval by the
Animal Care and Use Committee of Columbia University
was obtained before this study was begun. All animals
received humane care in compliance with the “Guide for
the Care and Use of Laboratory Animals” prepared by the
Institute of Laboratory Animal Resources and published
by the National Institutes of Health (NIH Publication
No. 86-23, revised 1985). Primates were housed in a
facility approved by the American Association for Labo-
ratory Animal Care.
Cardiac transplantation. Heterotopic cardiac xeno-
transplantations were performed as previously de-
scribed.11 In brief, day-old piglets were sedated with
intramuscular ketamine (Aveco, Fort Dodge, Iowa) and
intubated. General endotracheal anesthesia was main-
tained with isoflurane (Anaquest, Madison, Wis.). After
isolation of the great vessels, the innominate artery was
cannulated with a 20-gauge Angiocath catheter (Deseret
Co., Sandy, Utah). After transection of the left inferior
pulmonary vein and inferior vena cava, the heart was
arrested with cold (4° C) University of Wisconsin solution
(Du Pont Pharmaceuticals, Wilmington, Del.) and chilled
with topical cold saline solution. The heart was resected,
and the left atrial free wall, as well as the venae cavae, was
closed with 7-0 polypropylene suture. The pulmonary
artery was transected at its bifurcation and the aorta was
transected slightly shorter than the pulmonary artery. The
heart was then stored in cold saline solution as final
preparation of the recipient was completed.
Newborn baboons weighing 950 to 1300 gm (average
age 36 days control, 38 days experimental) were sedated
with ketamine, intubated, and maintained under general
isoflurane anesthesia. They underwent heterotopic car-
diac transplantation, with anastomosis of the graft aorta
and pulmonary artery to the common iliac artery and vein,
respectively. Rejection of the graft was determined by
cessation of graft contraction. At the time of rejection the
graft was explanted and the baboon was returned to its
mother. The nonparametric Mann-Whitney test was used
to determine a two-tailed p value.
Immunosuppression. All recipient baboons received
cyclosporine (CsA, Sandimmune, Sandoz Pharmaceuti-
Fig. 2. Micrograph at high power of a heterotopic pig cardiac xenograft placed into an unmedicated
newborn baboon. This specimen demonstrates a dense mononuclear cell infiltrate with only a scattering of
polymorphonuclear neutrophils. Tissue was obtained at the time of rejection (4 days). This specimen is
representative of all control grafts.
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cals, East Hanover, N.J.) 10 mg/kg daily by intramuscular
injection or intravenously from the day of transplantation
until rejection. Methylprednisolone sodium succinate
(Solu-Medrol, The Upjohn Company, Kalamazoo, Mich.)
15 mg/kg was given intravenously on the day of transplan-
tation. Daily steroid therapy was then tapered to 1 mg/kg
daily if intravenous access was maintained; otherwise it
was switched to 0.8 mg/kg daily of methylprednisolone
acetate by intramuscular injection (Depo-Medrol, Up-
john). In addition to the CsA and steroids, baboons
received mycophenolate mofetil (MMF, CellCept, Roche
Laboratories, Nutley, N.J.). One week before transplan-
tation, recipients received MMF 100 mg/kg every other
day by subcutaneous injection; once the transplant oper-
ation was done, they received daily injections. All immu-
nosuppression was stopped once the graft was rejected
and explanted. CsA and steroids were purchased through
the pharmacy at Columbia-Presbyterian Medical Center.
MMF was a gift of Roche Pharmaceuticals.
Serum samples. Recipient baboon serum was obtained
from the baboons 1 week before transplantation (before
immunosuppression), at the time of rejection, and after
graft explantation and cessation of immunosuppression
(postoperative days 14 and 21). As a control for the
induced anti-Gal response, additional serum samples were
taken from a newborn baboon that underwent the same
operation as the transplant recipients, but did not receive
a xenograft. Each sample was frozen and stored at –80° C.
The samples were thawed for the first time at the time of
antibody measurement.
Enzyme-linked immunosorbent assay studies with
a-Gal–bovine serum albumin. Anti-Gal activity in the
serum of the transplanted baboons was determined in
enzyme-linked immunosorbent assay (ELISA) using syn-
thetic a-galactosyl epitopes coupled to bovine serum
albumin (BSA) (Dextra, Reading, United Kingdom) as
the solid-phase antigen. Fifty microliters of a-gal–BSA at
a concentration of 10 mg/ml in carbonate buffer (pH 9.5)
was placed in microtiter wells (3129 plates; Falcon, Ox-
nard, Calif.) and incubated for 2 hours at 37° C and
overnight at 4° C. The plates were subsequently blocked
with 1% BSA in carbonate buffer (pH 9.5) to decrease
nonspecific binding of immunoglobulins. Fifty-microliter
serum aliquots in twofold serial dilution in phosphate-
buffered saline (PBS) solution containing 1% BSA and
starting at a dilution of 1:100 were then placed in the
wells. After 90 minutes’ incubation at room temperature,
the plates were washed five times with PBS solution
containing 0.05% Tween. Horseradish peroxidase-conju-
gated rabbit anti-human IgG or IgM (Dako, Carpinteria,
Calif.) was added at a dilution of 1:1000 to each well in 50
ml aliquots. The plates were further incubated for 1 hour
and washed with PBS-Tween. The color reaction was
developed with o-phenylenediamine dihydrochloride (Sig-
ma Chemical Co., St. Louis, Mo.), and the absorbance was
measured in an ELISA reader at 492 nm.
In our experience, the blocking of the ELISA plates
cannot completely prevent nonspecific human immuno-
globulin binding. Therefore, to assess the specific binding
of anti-Gal, we performed a parallel ELISA assay using
the neoglycoprotein N-acetyllactosamine (Gal-b-1-4Glc-
NAc-R)–BSA as a control solid-phase antigen. Primates
and other mammals usually lack antibodies to this
epitope, because it is normally expressed in various
amounts on mammalian cells. The specific binding of
anti-Gal was assessed at each serum dilution by subtract-
ing the optical density measured with N-acetyllac-
tosamine–BSA from those with a-gal–BSA.12
Fig. 3. Low-power micrograph of a heterotopic pig cardiac xenograft placed into a medicated newborn
baboon. Tissue was obtained at the time of rejection (6 days). This specimen is representative of all
medicated grafts. It demonstrates complement-mediated rejection, with diffuse hemorrhage and edema.
There is thrombosis of the artery supplying the myocardium in the upper right corner.
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Light microscopy and immunofluorescence. Tissue
specimens were placed in formalin, sectioned, and stained
with hematoxylin and eosin, or they were placed in
embedding medium (OCT compound; Miles, Naperville,
Ill.), snap-frozen in liquid nitrogen, and stored at –80° C.
Frozen tissue sections (4 m thick) were prepared in a
Leica cryostat (Leica, Heidelberg, Germany). The sec-
tions were air-dried, fixed with acetone, and washed with
PBS solution. Deposition of IgG, IgM, C3, and fibrin was
detected by incubating each section with fluorescein iso-
thiocyanate–conjugated goat antihuman antibodies
(Dako). After incubation, tissue sections were washed
with PBS solution and mounted with p-phenyenediamine/
glycerol solution. Sections were evaluated with a Leitz
DMRB epifluorescence microscope (Leica) and photo-
graphed.
Results
Survival. Triple immunosuppression increased
average graft life from 3.6 6 0.5 days (n 5 5) to
6.2 6 1.1 days (n 5 5, p 5 0.01, Table I). All of the
baboons tolerated the immunosuppression without
complication. After graft explantation the baboons
were returned to their mothers. The baboons have
not had any long-term ill effects from the medica-
tion. They have developed normally, with the first
baboon recipient now more than 1 year beyond
transplantation.
Histology. As shown in Figs. 1 and 2, grafts
explanted from untreated recipient animals demon-
strated extensive mononuclear cell infiltration. The
mononuclear cell infiltration was significantly less in
the grafts from the immunosuppressed baboons, but
these grafts had extensive areas of hemorrhage,
thrombosis, platelet aggregation, neutrophil infiltra-
tion, and edema. The graft in Fig. 3 functioned for 6
days and, at explantation, had areas of infarcted
myocardium. Fig. 4 shows a small artery in cross
section, with denudation of the endothelium, adher-
ence of neutrophils to the endothelial surface, and
marked damage to the endothelial cell surface.
Furthermore, fibrin is attached to the denuded
vascular wall, suggestive of intravascular coagula-
tion.
Immunofluorescence. In untreated animals, im-
munofluorescence demonstrated the early stages of
a humoral response to the graft, with mild focal
deposition of IgM, IgG, C3, and fibrin. In contrast,
all of the grafts explanted from the medicated
baboons showed diffuse and dense deposition of
IgM, C3, and complement, with mild deposition of
IgG (Figs. 5 to 8). These features are consistent with
antibody binding and complement activation despite
triple immunosuppressive therapy.
IgM anti-Gal levels. Preoperative newborn ba-
boon sera contained barely detectable levels of
anti-Gal IgM. All baboon recipients of a pig xeno-
graft produced anti-Gal IgM after transplantation.
Fig. 4. High-power micrograph of a heterotopic pig cardiac xenograft placed into a medicated newborn
baboon. Tissue was obtained at the time of rejection (6 days). This specimen is representative of all
medicated grafts. It demonstrates a small artery in cross section, with destruction of the endothelium,
thrombosis, and infiltration of neutrophils.
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Table II describes the changes in anti-Gal IgM
concentrations in one of the immunosuppressed
baboons. These changes are representative of those
seen in all of the baboon pig xenograft recipients.
The titer of anti-Gal was defined as the reciprocal of
serum dilution, which yields 1.5 O.D. (i.e., 50% of
maximum binding). Interestingly, the anti-Gal IgM
titer remained low in the baboon that did not
receive a pig xenograft.
The induced IgM anti-Gal response was associ-
ated with IgM deposition in the explanted graft.
Two weeks after graft explantation the serum titer
remained elevated, but by 3 months the IgM level
returned to a level consistent with antibody isotype
switching.
IgG anti-Gal levels. Before transplantation all of
the baboons had circulating anti-Gal IgG antibody
titers ranging from 20 to 320. The titer of anti-Gal
antibody was defined as the reciprocal of serum
dilution which yields 1.5 O.D. (i.e., 50% of maxi-
mum binding). At the time of graft explantation,
serum anti-Gal IgG antibodies were barely detect-
able. However, because IgG was detected by immu-
nofluorescence in the explanted graft, this finding
suggested that the majority of circulating IgG anti-
body had bound to the xenograft. After the removal
of the graft, the anti-Gal IgG antibody titers rose in
all of the baboons that received transplants. In every
instance the anti-Gal IgG titer remained elevated or
continued to rise at 3 weeks. Table III describes the
changes in anti-Gal IgG antibody concentration in
one of the immunosuppressed baboons. These
changes are representative of all baboon recipients
of a pig xenograft. In the one newborn baboon that
did not receive a xenograft, there was a gradual
decline in anti-Gal IgG antibody titer, consistent
with the expected decrease in passively acquired
maternal antibody.
Discussion
The results of this study indicate that CsA-based
triple immunosuppression at a dose tolerable by a
newborn baboon can increase graft survival. Despite
barely detectable levels of IgM anti-Gal xenoreac-
tive antibody at the time of engraftment, this immu-
nosuppressive regimen was not sufficient to prevent
an induced IgM xenoreactive antibody response that
led to graft loss on days 6 to 7. Interestingly, it
appears that the treated animals demonstrated a
less significant macrophage and natural killer cell
infiltrate than the untreated animals.
Probably because of the greater duration of xeno-
graft exposure, the serum antibody response was
more pronounced in treated recipients than in un-
medicated animals. This resulted in a delayed form
of humoral rejection with destruction of the entire
Fig. 5. Immunopathology of a heterotopic pig cardiac xenograft placed into a immunosuppressed
newborn baboon. Tissue samples were obtained at the time of rejection (6 days). These samples are
representative of all specimens obtained from the immunosuppressed baboons. There is significant
deposition of IgM.
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vascular bed resulting in ischemic infarction of the
myocardium. The time course of the induced hu-
moral response parallels that of a primary IgM
response to a new antigen.
In previous studies aimed at elucidating the mech-
anisms of human natural killer cell lysis of porcine
endothelium, we have observed two distinct activa-
tion pathways—one involving binding of xenoreac-
tive IgG to CD16 and another resulting from acti-
vation with interleukin-2 (lymphokine-activated
natural killer cell activity). Interleukin-2 augmented
lytic activity is approximately twofold greater than
Fig. 6. Immunopathology of a heterotopic pig cardiac xenograft placed into a immunosuppressed
newborn baboon. Tissue samples were obtained at the time of rejection (6 days). These samples are
representative of all specimens obtained from the immunosuppressed baboons. There is significant
deposition of C3.
Fig. 7. Immunopathology of a heterotopic pig cardiac xenograft placed into a immunosuppressed
newborn baboon. Tissue samples were obtained at the time of rejection (6 days). These samples are
representative of all specimens obtained from the immunosuppressed baboons. There is significant
deposition of fibrin.
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antibody-dependent cellular cytotoxicity and is,
therefore, likely to be of greater clinical significance.
We therefore suspect that the CsA-based immuno-
suppressive protocol used in this study may have
reduced interleukin-2 production and consequently
diminished natural killer cell lysis.
An induced donor-specific antibody response can
develop in some recipients of allografts. Why these
allografts usually are not rejected with the same
vigor as a xenograft may be attributed to several
factors. Xenoreactive anti-pig antibody is directed at
the a-Gal epitope, which is expressed as millions of
epitopes per cell in porcine cells of ectodermal and
mesenchymal origin, whereas allospecific antibody is
primarily directed against major histocompatibility
antigens, the distribution of which is less dense. On
the other hand, ABO-incompatible allografts are at
risk for complement-mediated injury.13 Like pig
xenografts, ABO-incompatible allografts express a
carbohydrate epitope, not in as great a distribution
as a-Gal, but greater than the major histocompati-
bility antigens. The greater distribution of antigen,
therefore, results in greater IgM binding and more
efficient complement activation. Additionally, mem-
brane-bound complement regulatory proteins (ho-
mologous restriction factor, decay-accelerating factor,
and membrane cofactor protein) are species-specific
and therefore probably less effective in protecting a
xenograft from complement-mediated injury.
The immunosuppressive regimen used in this
study is comparable with that used in clinical allo-
transplantation. We have previously demonstrated
that CsA given to baboons by intramuscular injec-
tion at a dose of 10 mg/kg daily will result in serum
trough concentration of 300 to 500 ng/ml.14 The
intraoperative steroid dose of 15 mg/kg is greater
Fig. 8. Immunopathology of a heterotopic pig cardiac xenograft placed into a immunosuppressed
newborn baboon. Tissue samples were obtained at the time of rejection (6 days). These samples are
representative of all specimens obtained from the immunosuppressed baboons. There is trace deposition
of IgG.
Table II. IgM anti-Gal ELISA
Time IgM titer
Preop. Absent
Rejection Absent
Two weeks 80
Three weeks 80
Three months 40
Titer is defined as the reciprocal of the dilution that yields 50% maximum
binding.
Table III. IgG anti-Gal ELISA
Time IgG titer
Preop. 20
Rejection Absent
Two weeks 640
Three weeks 1280
Three months 1280
Titer is defined as the reciprocal of the dilution that yields 50% maximum
binding.
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than that usually administered in clinical allotrans-
plantation, but it is equivalent to the dose used when
ABO-incompatible kidneys have been engrafted,
the clinical situation most analogous to this experi-
ment.15
In an attempt to inhibit the induced anti-Gal
xenoantibody response, we included an anti-B cell
agent in the protocol. MMF is a potent, selective,
noncompetitive, and reversible inhibitor of inosine
monophosphate dehydrogenase. MMF can inhibit
the de novo pathway of guanosine nucleotide syn-
thesis. Since T- and B-lymphocyte proliferation is
critically dependent on the de novo synthesis of
purines, MMF has potent cytostatic effects on lym-
phocytes. MMF can also inhibit proliferative re-
sponses of T- and B-lymphocytes to both mitogenic
and allogenic stimulation and potentially suppress
antibody formation by B-lymphocytes. At doses of
100 mg/kg, MMF has been shown to inhibit lympho-
cyte proliferation while allowing for the replication
of intestinal basal epithelial cells and germinal
cells.16
MMF was inadequate to prevent the marked
induction of xenoreactive antibody in this model.
Additional strategies to prevent complement-medi-
ated xenograft injury will be required to achieve
clinically relevant graft prolongation. Such strategies
are presently being used in our laboratory and
include porcine organs transgenic for human com-
plement-regulatory proteins. It is expected that
these organs may one day be used as “a bridge” to
allotransplantation, sustaining newborn human be-
ings in need of a heart transplant until an appropri-
ate donor can be found.
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